IntraBio Seeks European Approval for Ataxia-Telangiectasia Treatment

IntraBio has submitted an application to the European Medicines Agency to expand the approved use of AQNEURSA to include the treatment of Ataxia-Telangiectasia. This marks the first regulatory submission to the EMA for a therapy specifically targeting this rare, progressive neurodegenerative disorder. The application will now undergo validation before commencing a formal scientific review process.